Cargando…

Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study

BACKGROUND: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined. METHODS: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Fielding, Katherine L, Charalambous, Salome, Stenson, Amy L, Pemba, Lindiwe F, Martin, Des J, Wood, Robin, Churchyard, Gavin J, Grant, Alison D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494994/
https://www.ncbi.nlm.nih.gov/pubmed/18631397
http://dx.doi.org/10.1186/1471-2334-8-93
_version_ 1782158257041702912
author Fielding, Katherine L
Charalambous, Salome
Stenson, Amy L
Pemba, Lindiwe F
Martin, Des J
Wood, Robin
Churchyard, Gavin J
Grant, Alison D
author_facet Fielding, Katherine L
Charalambous, Salome
Stenson, Amy L
Pemba, Lindiwe F
Martin, Des J
Wood, Robin
Churchyard, Gavin J
Grant, Alison D
author_sort Fielding, Katherine L
collection PubMed
description BACKGROUND: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined. METHODS: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and risk factors for suboptimal virological outcome, defined as plasma HIV-1 viral load >= 400 copies/ml. RESULTS: Among 1760 individuals starting ART before July 2004, 1172 were in follow-up at 12 months of whom 953 (81%) had a viral load measurement (median age 41 yrs, 96% male, median baseline CD4 count 156 × 10(6)/l). 71% (681/953) had viral load < 400 copies/ml at 12 months. In a multivariable analysis, independent predictors of suboptimal virological outcome at 12 months were <1 log decrease in viral load at six weeks (odds ratio [OR] 4.71, 95% confidence interval [CI] 2.56–8.68), viral load at baseline (OR 3.63 [95% CI 1.88–7.00] and OR 3.54 [95% CI 1.79–7.00] for 10,001–100,000 and >100,000 compared to <= 10,000 copies/ml, respectively), adherence at six weeks (OR 3.50 [95% CI 1.92–6.35]), WHO stage (OR 2.08 [95% CI 1.28–3.34] and OR 2.03 [95% CI 1.14–3.62] for stage 3 and 4 compared to stage 1–2, respectively) and site of ART delivery. Site of delivery remained an independent risk factor even after adjustment for individual level factors. At 6 weeks, of 719 patients with self-reported adherence and viral load, 72 (10%) reported 100% adherence but had <1 log decrease in viral load; conversely, 60 (8%) reported <100% adherence but had >= 1 log decrease in viral load. CONCLUSION: Virological response at six weeks after ART start was the strongest predictor of suboptimal virological outcome at 12 months, and may identify individuals who need interventions such as additional adherence support. Self reported adherence was less strongly associated but identified different patients compared with viral load at 6 weeks. Site of delivery had an important influence on virological outcomes; factors at the health system level which influence outcome need further investigation to guide development of effective ART programmes.
format Text
id pubmed-2494994
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24949942008-08-05 Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study Fielding, Katherine L Charalambous, Salome Stenson, Amy L Pemba, Lindiwe F Martin, Des J Wood, Robin Churchyard, Gavin J Grant, Alison D BMC Infect Dis Research Article BACKGROUND: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined. METHODS: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and risk factors for suboptimal virological outcome, defined as plasma HIV-1 viral load >= 400 copies/ml. RESULTS: Among 1760 individuals starting ART before July 2004, 1172 were in follow-up at 12 months of whom 953 (81%) had a viral load measurement (median age 41 yrs, 96% male, median baseline CD4 count 156 × 10(6)/l). 71% (681/953) had viral load < 400 copies/ml at 12 months. In a multivariable analysis, independent predictors of suboptimal virological outcome at 12 months were <1 log decrease in viral load at six weeks (odds ratio [OR] 4.71, 95% confidence interval [CI] 2.56–8.68), viral load at baseline (OR 3.63 [95% CI 1.88–7.00] and OR 3.54 [95% CI 1.79–7.00] for 10,001–100,000 and >100,000 compared to <= 10,000 copies/ml, respectively), adherence at six weeks (OR 3.50 [95% CI 1.92–6.35]), WHO stage (OR 2.08 [95% CI 1.28–3.34] and OR 2.03 [95% CI 1.14–3.62] for stage 3 and 4 compared to stage 1–2, respectively) and site of ART delivery. Site of delivery remained an independent risk factor even after adjustment for individual level factors. At 6 weeks, of 719 patients with self-reported adherence and viral load, 72 (10%) reported 100% adherence but had <1 log decrease in viral load; conversely, 60 (8%) reported <100% adherence but had >= 1 log decrease in viral load. CONCLUSION: Virological response at six weeks after ART start was the strongest predictor of suboptimal virological outcome at 12 months, and may identify individuals who need interventions such as additional adherence support. Self reported adherence was less strongly associated but identified different patients compared with viral load at 6 weeks. Site of delivery had an important influence on virological outcomes; factors at the health system level which influence outcome need further investigation to guide development of effective ART programmes. BioMed Central 2008-07-16 /pmc/articles/PMC2494994/ /pubmed/18631397 http://dx.doi.org/10.1186/1471-2334-8-93 Text en Copyright © 2008 Fielding et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fielding, Katherine L
Charalambous, Salome
Stenson, Amy L
Pemba, Lindiwe F
Martin, Des J
Wood, Robin
Churchyard, Gavin J
Grant, Alison D
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
title Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
title_full Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
title_fullStr Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
title_full_unstemmed Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
title_short Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
title_sort risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in south africa: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494994/
https://www.ncbi.nlm.nih.gov/pubmed/18631397
http://dx.doi.org/10.1186/1471-2334-8-93
work_keys_str_mv AT fieldingkatherinel riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy
AT charalamboussalome riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy
AT stensonamyl riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy
AT pembalindiwef riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy
AT martindesj riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy
AT woodrobin riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy
AT churchyardgavinj riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy
AT grantalisond riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy